ClinicalTrials.gg
RecruitingNCT03687606IHHUpdated Apr 8, 2020

Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH)

A Phase 4 interventional study of Human Chorionic Gonadotropin and human menopausal gonadotropin in Isolated Hypogonadotropic Hypogonadism, Kallmann Syndrome and Infertility, sponsored by Tongji Hospital. Recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2020-04-08.

Primary conditionKallmann SyndromeRegistry: HypogonadismReclassifiedWhy we changed it
Registry
Hypogonadism — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kallmann Syndrome
Why
  1. The study's listed conditions name Kallmann Syndrome, a narrower term within Hypogonadism.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tongji Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2018; still recruiting 8 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This study will evaluate the efficacy and safety of long term use of hCG alone or hCG plus hMG in the treatment of male patients with isolated hypogonadotropic hypogonadism (IHH). One third of the participants will receive hCG treatment alone and the other third of the participants will receive hCG treatment alone for six months, then the hMG will be added. And the last third of the participants will receive hCG and hMG treatment since the beginning of the treatment.

Read the detailed description

The efficacy of hCG alone or hCG plus hMG in the treatment of male IHH patients was reported in some studies. However, these studies were mostly non-randomized controlled studies with small size of samples and short follow-up time. There was also no reported study which aimed to compare the efficacy and safety of long term use of hCG or hCG plus hMG in the treatment of male patients with IHH. So the difference in the efficacy and safety between long term use of hCG alone and hCG plus hMG in the treatment of IHH is unknown. In different reported studies, the hCG plus hMG treatment had two regimens: using hCG alone for six month, then hMG was added and using hCG plus hMG since the beginning of the treatment. The difference in the efficacy and safety between the above two regimes is also unknown.

02

Conditions studied

  • Isolated Hypogonadotropic Hypogonadism
  • Kallmann Syndrome
  • Infertility

Browse trials for

Keywords

  • Gonadotropin treatment
  • human chorionic gonadotropin
  • human menopausal gonadotropin
03

In context

Kallmann Syndrome Reclassified

23 studies on the registry are indexed under Kallmann Syndrome; 5 are open to participants now.

This study's planned enrollment of 210 is above the median of 75 across 14 interventional studies indexed under Kallmann Syndrome.

Browse Kallmann Syndrome studies →

Lead sponsor

Tongji Hospital is the lead sponsor of 392 studies on the registry; 213 are open to participants now.

Compared within Kallmann Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypogonadism. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18, ≤ 45 years old;
  2. Adolescent dysplasia or loss of puberty: Genital Tanner score ﹤ 5, pubic hair Tanner score ﹤ 5;
  3. Serum FSH and LH levels are low or in normal low value, testosterone was lower than normal range (1.75ng / ml, the lower limit of the normal blood testosterone reference range of Tongji Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology);
  4. With or without olfactory loss/reduction;
  5. Other pituitary hormone levels are normal;
  6. Head MRI examination is normal;
  7. Fertility is desired currently or will be desired in the future;
  8. Understand and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Primary hypogonadism;
  2. Acquired hypogonadotrophic hypogonadism;
  3. A history of treatment with pulsed GnRH, hCG and FSH related hormones;
  4. Receive testosterone replacement therapy for more than 6 months;
  5. History of cryptorchidism or cryptorchidism;
  6. The sperm density before treatment ≥1×10\^6/ml;
  7. Moderate or severe liver and kidney dysfunction (>120IU/L, AST>80IU/L, CR>115μmol/L);
  8. The karyotype is 45,X or 47,XXY and 48, XXXY and other abnormal karyotypes;
  9. True hermaphroditism and pseudohermaphroditism;
  10. Sex hormone abnormalities caused by adrenal lesions;
  11. Hypogonadism secondary to other systemic diseases;
  12. Abnormal secretion of hormones caused by brain lesions (such as pituitary tumors);
  13. There are other hormone abnormalities in the pituitary;
  14. There are for the treatment with hCG or hMG.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Active comparator
    Human Chorionic Gonadotropin alone

    Human Chorionic Gonadotropin 2000U\~6000U, intramuscular injection, two times per week for 3 years.

    Drug: Human Chorionic Gonadotropin

  • Experimental
    hCG alone for 6 months then hMG added

    Human Chorionic Gonadotropin 2000U\~6000U, intramuscular injection, two times per week for six months, then 75\~150IU human menopausal gonadotropin, intramuscular injection, two times per week, was added and last for the next 30 months.

    Drug: Human Chorionic Gonadotropin · Drug: human menopausal gonadotropin

  • Experimental
    hCG and hMG

    Human Chorionic Gonadotropin 2000U\~6000U and 75\~150IU human menopausal gonadotropin, intramuscular injection, two times per week for 3 years.

    Drug: Human Chorionic Gonadotropin · Drug: human menopausal gonadotropin

Interventions

06

What researchers measure

Primary outcomes

  1. Sperm density

    Sperm density will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.

    Time frame: 6 months.

Secondary outcomes

  1. Semen volume

    Sperm volume will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.

    Time frame: 6 months.

  2. Sperm activity

    Sperm activity will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.

    Time frame: 6 months.

  3. The time for sperm to appear during treatment

    The time for the sperm firstly appeared in the semen will be recorded.

    Time frame: 6 months.

  4. Serum testosterone levels

    The serum testosterone levels will be tested in every visit.

    Time frame: 3 months.

  5. Testicular volume

    Testicular volume will be measured using a Prader orchidometer.

    Time frame: 3 months.

  6. Penis length

    Penis length will be measured from the pubic symphysis to glans using a vernier caliper.

    Time frame: 3 months.

  7. Pubic hair

    Pubic hair will be evaluated according to Tanner pubertal stages.

    Time frame: 3 months.

  8. Genitalia

    Genitalia will be evaluated according to Tanner pubertal stages.

    Time frame: 3 months.

Other outcomes

  1. Height

    Height will be measured at every visit.

    Time frame: 3 months.

  2. Weight

    Weight will be measured at every visit.

    Time frame: 3 months.

  3. Feeling of inferiority scale score

    Feeling of inferiority scale scores will be obtained using feeling of inferiority scale.

    Time frame: 3 months.

07

Study locations

1 of 1 sites recruiting
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
    Recruiting
    • Hao Xu, M.D · Contact+86-15872427301
08

References and documents

Publications

  • Zacharin M, Sabin MA, Nair VV, Dabadghao P. Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth and may promote early spermatogenesis. Fertil Steril. 2012 Oct;98(4):836-42. doi: 10.1016/j.fertnstert.2012.06.022. Epub 2012 Jul 3. Erratum In: Fertil Steril. 2013 May;99(6):1798. Dagabdhao, Preeti [corrected to Dabadghao, Preeti]. PubMed 22763096 ↗
  • Matsumoto AM, Snyder PJ, Bhasin S, Martin K, Weber T, Winters S, Spratt D, Brentzel J, O'Dea L. Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f): long-term treatment in azoospermic men with hypogonadotropic hypogonadism. Fertil Steril. 2009 Sep;92(3):979-990. doi: 10.1016/j.fertnstert.2008.07.1742. Epub 2008 Oct 18. PubMed 18930190 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data for all primary and secondary outcome measure will be available.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data will be available with 6 months of study completion.

Access criteria: Data access requests will be reviewed by the external independent review panel and Tongji hospital. Requester will be reqiured to sign a Data Acces Agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2018 (actual). Primary completion is estimated for Oct 2024, 71 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2018
First posted
Sep 27, 2018
StartActual
Oct 18, 2018
Primary completionEst.
Oct 1, 2024
CompletionEst.
Oct 1, 2025
Last update
Apr 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03687606
Lead sponsor
Tongji Hospital
Responsible party
Jihong Liu (Principal Investigator, Clinical Professor, Tongji Hospital) — Principal investigator
First posted
Sep 27, 2018
Start date
Oct 18, 2018
Primary completion
Oct 1, 2024 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
Apr 8, 2020

Study contacts

Hao Xu, M.D
Contact
haoxutjmu@163.com
+86-15872427301
Yinwei Chen, M.D
Contact
913904361@qq.com
+86-15527953877
Jihong Liu, M.D
principal investigator · Departments of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Menotropins

Start the discussion